The PGE2 synthesis enzyme COX-2, a target for non-steroidal antiinflammatory drugs including selective inhibitors, emerged as one such factor (7, 21) and has been shown to support an immunosuppressive TME in other cancer types as well (10, 34, 51). This evidence concerns the gene PTGER2 and cancer.